Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
about
The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic InitiativeSafety issues of current analgesics: an updateAdverse Drug Reactions in a Tertiary Care Emergency Medicine Ward - Prevalence, Preventability and ReportingAdverse drug reactions to anticoagulants in Spain: analysis of the Spanish National Hospital Discharge Data (2010-2013).Vigi4Med Scraper: A Framework for Web Forum Structured Data Extraction and Semantic Representation.Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures.Epidemiology of adverse drug reactions in Europe: a review of recent observational studiesPerioperative management of antithrombotic and antiplatelet therapyIndividualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.Hospitalizations Due to Adverse Drug Events in the Elderly-A Retrospective Register StudyPrevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study.Potentially high-risk medication categories and unplanned hospitalizations: a case-time-control study.Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists.Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Development and validation of hospital information system-generated indicators of the appropriateness of oral anticoagulant prescriptions in hospitalised adults: the PACHA study protocol.Hospitalizations due to preventable adverse reactions-a systematic review.Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users.Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years.Compliance of psychotropic drug prescription with clinical practice guidelines in older inpatients.Drug-Related Inadvertent Deaths in a University Hospital--A Declining Trend.Preventability of adverse effects of analgesics: analysis of spontaneous reports.Early rehospitalizations of frail elderly patients - the role of medications: a clinical, prospective, observational trialAdverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.Preventable ADRs leading to hospitalization - results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients.Professional, structural and organisational interventions in primary care for reducing medication errors.Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus.
P2860
Q26764776-83F66F19-BA74-4EC3-A598-D1126D1D7656Q26777293-1257BCF0-084D-400F-B41C-FF657EC75F0FQ28554059-70692D47-4925-4DEC-ADCC-3F29250AED72Q31154098-F9FF14A4-0B1B-4271-B7BA-46A02B0BE5B4Q31156727-918DB1F3-799B-4638-B304-FA7C4AA7330BQ33656869-B40ABA62-998F-43F5-A2FE-A1C88CB07E0FQ35546999-7FCE9DCC-3A20-4046-B0F3-A9EEA2DD8D3EQ35758792-FDBC6300-C0ED-460C-97E2-624F0D0FBE4CQ35998552-9B62F6AC-3E66-4150-9B32-3E549E71C54CQ37312143-7196194A-2244-495A-9A82-6DC3691BDDFDQ37399578-A28AC23C-F667-423B-B834-158844B5E3AEQ37598383-BF1B4B2D-CF4E-4A23-991E-539070F3F90DQ37605761-4004FEA6-F4D3-42ED-9426-3269EF49D526Q37624211-88FEF90B-206D-4D11-BD8D-77D92BF7DC4CQ38393997-7BDE5279-498D-438F-80F9-2D398D00C4B5Q38599156-6D476830-1093-426D-8E88-CA09260A370EQ39028094-51183444-CDE2-4E82-8418-E48A3D0D297CQ39336264-BF4F8A77-EE70-43D0-8CA3-652DE838C1CBQ39882062-6DDB2A7D-5FCC-46E5-B01A-FA90A30FC0C0Q39991967-B6EBE509-121F-4CED-A07C-35CA2347A578Q40336391-BE291344-7207-442C-9237-3C461A551599Q40796795-D9DF21DA-3A3D-49D5-B8B7-CFE1F0C8A32FQ41305333-F7FACB07-8223-4A45-B439-E84FA49FD168Q41522418-8EB2DF63-EC41-4B29-AD4B-ED9E1F8271DFQ47186746-84A62ACF-564B-4D23-9B15-5CE0D5936FF8Q47573647-60B85E56-7792-40EA-A74F-40808BC41D95Q47865717-EE02EC87-7801-4061-8294-15212CF6CCF0Q50548817-BF046D87-67E2-4111-82E5-04273D07D8B8
P2860
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
@en
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
@nl
type
label
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
@en
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
@nl
prefLabel
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
@en
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
@nl
P2093
P2860
P356
P1476
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study
@en
P2093
Anne Bénard-Laribière
EMIR Study Group on behalf of the French network of pharmacovigilance centres
Françoise Haramburu
Ghada Miremont-Salamé
Marie-Christine Pérault-Pochat
P2860
P304
P356
10.1111/FCP.12088
P577
2014-09-25T00:00:00Z